Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 181 av 181 resultater
Tid
Selskap
Tittel
Sektor
Kategori
09 Nov 2021
14:00 CET
TRANSGENE
Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021
20103010 Biotechnology
New
04 Nov 2021
17:45 CET
TRANSGENE
Transgene Reports Business Update and Q3 2021 Financial Position
20103010 Biotechnology
Income
04 Nov 2021
17:45 CET
TRANSGENE
Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021
20103010 Biotechnology
Income
01 Oct 2021
15:00 CEST
TRANSGENE
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
20103010 Biotechnology
Products and services
01 Oct 2021
15:00 CEST
TRANSGENE
Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021
20103010 Biotechnology
Products and services
22 Sep 2021
17:45 CEST
TRANSGENE
Progression des deux plateformes innovantes de Transgene et visibilité financière étendue à fin 2023
20103010 Biotechnology
Other financial transaction
22 Sep 2021
17:45 CEST
TRANSGENE
Mise à disposition du Rapport Financier Semestriel au 30 juin 2021
20103010 Biotechnology
Income
22 Sep 2021
17:45 CEST
TRANSGENE
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
20103010 Biotechnology
Other financial transaction
22 Sep 2021
17:45 CEST
TRANSGENE
Availability of Transgene’s Half-Year Financial Report as of June 30, 2021
20103010 Biotechnology
Income
16 Sep 2021
08:30 CEST
TRANSGENE
Transgene présente des données de Phase I confirmant le potentiel du virus oncolytique TG6002
20103010 Biotechnology
Other subject
16 Sep 2021
08:30 CEST
TRANSGENE
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
20103010 Biotechnology
Other subject
13 Sep 2021
08:00 CEST
TRANSGENE
Transgene Announces Upcoming Investor Meetings
20103010 Biotechnology
Meetings / events
13 Sep 2021
08:00 CEST
TRANSGENE
Transgene annonce ses prochaines rencontres avec les investisseurs
20103010 Biotechnology
Meetings / events
01 Sep 2021
17:45 CEST
TRANSGENE
Transgene Participates in New Cancer Research Consortium
20103010 Biotechnology
Other subject
01 Sep 2021
17:45 CEST
TRANSGENE
Transgene participe à un nouveau consortium de recherche contre le cancer
20103010 Biotechnology
Other subject
06 Jul 2021
18:00 CEST
TRANSGENE
Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of June 30, 2021
20103010 Biotechnology
Other financial transaction
06 Jul 2021
18:00 CEST
TRANSGENE
Transgene : Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2021
20103010 Biotechnology
Other financial transaction
28 Jun 2021
07:00 CEST
TRANSGENE
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
20103010 Biotechnology
Products and services
28 Jun 2021
07:00 CEST
TRANSGENE
Premier patient inclus au Royaume-Uni dans l’essai de Phase I de TG4050 (plateforme myvac®), l’immunothérapie individualisée de Transgene
20103010 Biotechnology
Products and services
24 Jun 2021
17:45 CEST
TRANSGENE
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
20103010 Biotechnology
Other subject
24 Jun 2021
17:45 CEST
TRANSGENE
Transgene : Inclusion du premier patient dans l’essai de Phase II de TG4001 + avelumab vs avelumab dans les cancers anogénitaux HPV16-positifs
20103010 Biotechnology
Other subject
22 Jun 2021
07:00 CEST
TRANSGENE
Transgene Announces the Success of Its Capital Increase via a Private Placement
20103010 Biotechnology
Share introduction and issues
22 Jun 2021
07:00 CEST
TRANSGENE
Transgene annonce le succès de son augmentation de capital par placement privé
20103010 Biotechnology
Share introduction and issues
21 Jun 2021
18:16 CEST
TRANSGENE
Transgene lance une augmentation de capital par placement privé
20103010 Biotechnology
Other subject
21 Jun 2021
18:16 CEST
TRANSGENE
Transgene Launches a Capital Increase via a Private Placement
20103010 Biotechnology
Other subject
08 Jun 2021
17:45 CEST
TRANSGENE
Transgene renforce les droits de propriété intellectuelle de ses virus oncolytiques codant pour des inhibiteurs de points de contrôle (ICI)
20103010 Biotechnology
Other subject
08 Jun 2021
17:45 CEST
TRANSGENE
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
20103010 Biotechnology
Other subject
27 May 2021
08:30 CEST
TRANSGENE
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
20103010 Biotechnology
Other subject
27 May 2021
08:30 CEST
TRANSGENE
Transgene et BioInvent obtiennent l’autorisation IND « Investigational New Drug » de la FDA américaine pour BT-001, un virus oncolytique contre les tumeurs solides
20103010 Biotechnology
Other subject
26 May 2021
17:45 CEST
TRANSGENE
Transgene: Combined General Meeting of May 26, 2021
20103010 Biotechnology
General meeting / Board Meeting
26 May 2021
17:45 CEST
TRANSGENE
Transgene : Assemblée Générale Mixte du 26 mai 2021
20103010 Biotechnology
General meeting / Board Meeting
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva